Find Reports

Select Report Type

Reimbursement Review

Displaying 301 - 325 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
encorafenib and binimetinib	Braftovi and Mektovi	encorafenib and binimetinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Advanced Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 16, 2020	Jul 26, 2021	PC0232-000
dinutuximab	Unituxin	dinutuximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Neuroblastoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 23, 2020	Jul 23, 2021	PC0222-000
ozanimod	Zeposia	ozanimod	SR0652 Zeposia - CDEC Final Recommendation June 29, 2021_for posting.pdf Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Multiple Sclerosis, relapsing - remitting	Do not reimburse	Complete	Aug 25, 2020	Jun 23, 2021	SR0652-000
tildrakizumab	Ilumya	tildrakizumab	Recommendation and Reasons: Updated Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2019	Jun 21, 2021	SR0624-000
fedratinib	Inrebic	fedratinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation Clinician Input	Myelofibrosis	Reimburse with clinical criteria and/or conditions	Complete	Nov 5, 2020	Jun 21, 2021	PC0205-000
semaglutide	Rybelsus	semaglutide	Recommendation and Reasons: Updated Recommendation and Reasons - Original Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0637-000
luspatercept	Reblozyl	luspatercept	CADTH_reimbursement_recommendation_luspatercept_(reblozyl).pdf Reblozyl - Patient Group Input for Posting.pdf Stakeholder feedback on Draft Recommendation Clinical and Pharmacoeconomic combined Report	beta-thalassemia associated anemia	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0669-000
dupilumab	Dupixent	dupilumab	CADTH_reimbursement_recommendation_dupilumab_(dupixent).pdf SR0667 Dupixent - Patient Input Submission_For Posting.pdf Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation Clinician Input	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0667-000
patiromer	Veltassa	patiromer	CADTH_reimbursement_recommendation_patiromer_(veltassa).pdf SR0665 Veltassa - Patient Input Submission.pdf Clinical and Pharmacoeconomic combined Report Clinician Input Stakeholder Feedback on Draft Recommendation	Hyperkalemia, adults (chronic kidney disease)	Reimburse with clinical criteria and/or conditions	Complete	Oct 30, 2020	Jun 8, 2021	SR0665-000
Dabrafenib and Trametinib for ...	Tafinlar and Mekinist	Dabrafenib and Trametinib	10226Dabrafenib-TrametinibNSCLC_inRec_pERC Chair Approved_Post01Apr2021_final.pdf Dabrafenib-Trametinib NSCLC BRAF V600 – pERC Final Recommandation Dabrafenib-Trametinib NSCLC BRAF V600 – Final Economic Guidance Report Dabrafenib-Trametinib NSCLC BRAF V600 – Final Clinical Guidance Report Dabrafenib-Trametinib NSCLC BRAF V600 – PAG Feedback on Initial Recommendation Dabrafenib-Trametinib NSCLC BRAF V600 – Manufacturer Feedback on Initial Recomm…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group Feedback on Init…Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician Feedback on Initial Recommend…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group COI Declarations Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician COI Declarations	NSCLC BRAF V600	Reimburse with clinical criteria and/or conditions	Complete	Oct 1, 2020	May 28, 2021	PC0226-000
ranolazine	Corzyna	ranolazine	sr0655CL-corzyna.pdf sr0655PE-corzyna.pdf Reasons and Recommendations	Stable angina pectoris, adults	Do not reimburse	Complete	Aug 17, 2020	May 27, 2021	SR0655-000
Chronic Lymphocytic Leukemia			Final Report	B-Cell Precursor Acute Lymphoblastic Leukemia		Completed		May 18, 2021	PH0004-000
Sonidegib (Odomzo) for Basal C...	Odomzo	Sonidegib	10215SonidegibBCC_fnRec_Post29Apr2021_final.pdf 10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf 10215SonidegibBCC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10215SonidegibBCC_inRec_Post04Mar2021_final.pdf 10215SonidegibBCC_PAGFeedbackSummary_Post29Apr2021_final.pdf 10215SonidegibBCC_SponsorFeedback_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientFeedback_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianFeedback_CCO_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientCOI_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianInput_Combined_COIs Post29Apr2021_final_Redacted.pdf	Basal Cell Carcinoma	Do not reimburse	Complete	Jun 19, 2020	Apr 29, 2021	PC0215-000
Niraparib (Zejula) for first l...	Zejula	Niraparib	10224NiraparibOC_fnRec_pERC Chair Approved_Post29Apr2021_final.pdf 10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf 10224NiraparibOC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10224NiraparibOC_inRec_pERC Chair Approved_Post04Mar2021_final.pdf 10224NiraparibOC_PAGFeedbackSummary_Post29Apr2021_final_Redacted.pdf 10224NiraparibOC_SponsorFeedback_Post29Apr2021_final.pdf 10224NiraparibOC_PatientFeedback_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_ClinicianFeedback_CCO_Post29Apr2021_final.pdf 10224NiraparibOC_Patient COI_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_Combined Clinician COIs_Post29Apr2021_final.pdf	First Line OC	Reimburse with clinical criteria and/or conditions	Complete	Sep 21, 2020	Apr 29, 2021	PC0224-000
infliximab	Remsima	infliximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions	Rheumatoid arthritis	Reimburse with clinical criteria and/or conditions	Complete	Sep 24, 2020	Apr 22, 2021	SR0659-000
Polatuzumab Vedotin (Polivy) f...	Polivy	Polatuzumab Vedotin	10227PolatuzumabDLBCL_fnRec_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_inRec_pERC Chair Approved_Post01Apr2021_final.pdf 10227PolatuzumabDLBCL_PAG Feedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_SponsorFeedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_PatientFeedback_LC_Final_Redacted.pdf 10227PolatuzumabDLBCL_ClinicianFeedback_CCO_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Patient COI_LC_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Combined Clinician COIs EC21Apr2021_final_Redacted.pdf	Diffuse large B-cell lymphoma (DLBCL)	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2020	Apr 21, 2021	PC0227-000
Brigatinib (Alunbrig) for Anap...	Alunbrig	Brigatinib	10230BrigatinibALK+NSCLC_fnRec_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_inRec_approvedbyChair_Post01Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PAGFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_SponsorFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PatientFeedback_LCC_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined ClinicianFeedback_EC21Apr2021.pdf 10230BrigatinibALK+NSCLC_Patient COI_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined_COIs EC21Apr2021_final.pdf	(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 30, 2020	Apr 21, 2021	PC0230-000
Olaparib (Lynparza) for metast...	Lynparza	Olaparib	10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf 10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf 10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Patient COI_CCSN_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Combined Clinician COI_EC21Apr2021_final_Redacted.pdf	metastatic castration-resistant prostate cancer (mCRPC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 22, 2020	Apr 21, 2021	PC0223-000
satralizumab	Enspryng	satralizumab	SR0663 Enspryng - CDEC Final Recommendation April 23, 2021_for posting.pdf SR0663 Enspryng - Patient Input Group - For posting.pdf Clinical Review Report	Neuromyelitis optica spectrum disorder	Reimburse with clinical criteria and/or conditions	Complete	Oct 22, 2020	Apr 21, 2021	SR0663-000
Unresectable Hepatocellular Ca...			Final Report	Unresectable Hepatocellular Carcinoma		Complete		Apr 21, 2021	PH0003-000
amifampridine	Ruzurgi	amifampridine	SR0660 Ruzurgi - CDEC Final Recommendation April 23, 2021_For posting.pdf sr0660-ruzurgi-clinical-review-report.pdf sr0660-ruzurgi-pharmacoeconomic-review-report.pdf	Lambert-Eaton myasthenic syndrome	Reimburse with clinical criteria and/or conditions	Complete	Oct 5, 2020	Apr 20, 2021	SR0660-000
Isatuximab (Sarclisa) for Mult...	Sarclisa	Isatuximab	10220IsatuximabMM_fnRec_pERC Chair Approved_Post01Apr2021_final.pdf 10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf 10220IsatuximabMM_fnCGR_NOREDACT_Post01Apr2021_final.pdf 10220IsatuximabMM_inRec_pERC Chair Approved_Post4Feb2021_final.pdf 10220IsatuximabMM_PAGFeedbackSummary_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_SponsorFeedback_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_PatientFeedback_MC_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_ClinicianFeedback_CCO_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_Patient_COI_MyelomaCanada_Post01Apr2021_final.pdf 10220IsatuximabMM_Clinician_Combined_COIs_Post_final_Redacted.pdf	Multiple Myeloma	Reimburse with clinical criteria and/or conditions	Complete	Aug 17, 2020	Apr 1, 2021	PC0220-000
sacubitril/valsartan	Entresto	sacubitril/valsartan	SR0644 Entresto - CDEC Final Recommendation March 26, 2021 (Redacted)_for Posting.pdf SR0644_Entresto Resubmission_PI Submission.pdf	Heart failure, NYHA Class II or III	Reimburse with clinical criteria and/or conditions	Complete	May 22, 2020	Mar 24, 2021	SR0644-000
fremanezumab	Ajovy	fremanezumab	Recommendation and Reasons Clinical Report Pharmacoeconomic Report Patient Group Input Submission	migraine	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2020	Mar 24, 2021	SR0641-000
onasemnogene abeparvovec	Zolgensma	onasemnogene abeparvovec	Recommendation and Reasons Clinical Report Pharmacoeconomic Report Patient Group Input Submission Implementation Advice	Spinal muscular atrophy (SMA), pediatrics	Reimburse with clinical criteria and/or conditions	Complete	Jun 25, 2020	Mar 24, 2021	SG0649-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 301 - 325 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Risk Factors and Preventive Interventions for Post‒COVID-19 condition		Apr 11, 2022	Systematic Review	Complete	RE0039-000
Metered-Dose Inhalers for Medical Cannabis Use	Metered-Dose Inhalers for Medical Cannabis Use	Apr 11, 2022	Rapid Review	Completed	RC1417-000
Robotic-Assisted Surgical Systems for Hip Arthroplasty	Robotic-Assisted Surgical Systems for Hip Arthroplasty	Apr 6, 2022	Rapid Review	Completed	RC1412-000
Therapeutic Mattresses for Chronic Pain	Therapeutic Mattresses for Chronic Pain	Apr 6, 2022	Rapid Review	Completed	RC1415-000
Dementia Concerns and Considerations: Our Panel of People With Lived Experience	Dementia Concerns and Considerations: Our Panel of People With Lived Experience	Apr 1, 2022	Technology Review	Completed	EH0107-000 - HC0022-000
Intraocular Lenses for Infants with Aphakia	Intraocular Lenses for Infants With Aphakia - Health Technology Review Intraocular Lenses for Infants With Aphakia - Project Protocol (Amended Report)Intraocular Lenses for Infants With Aphakia - Project Protocol (Superseded Repo…In Brief: Intraocular Lenses for Infants With Aphakia	Mar 31, 2022	Systematic Review	Complete	RE0036-000
Folate Testing in People With Suspected Folate Deficiency	Folate Testing in People With Suspected Folate Deficiency	Mar 28, 2022	Rapid Review	Completed	RC1414-000
Vitamin B12 Testing in People with Suspected Vitamin B12 Deficiency	Vitamin B12 Testing in People with Suspected Vitamin B12 Deficiency	Mar 24, 2022	Rapid Review	Completed	RC1413-000
Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveitis	Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveit…	Mar 16, 2022	Rapid Review	Completed	RD0064-000
Robotic-Assisted Surgical Systems for Knee Arthroplasty	Robotic-Assisted Surgical Systems for Knee Arthroplasty	Mar 16, 2022	Rapid Review	Completed	RC1411-000
Custom-Made Foot Orthotics for People with Lower Limb Conditions	Custom-Made Foot Orthotics for People with Lower Limb Conditions	Feb 18, 2022	Rapid Review	Completed	RC1410-000
Anakinra Therapy for Hemophagocytic Lymphohistiocytosis	Anakinra Therapy for Hemophagocytic Lymphohistiocytosis	Feb 16, 2022	Rapid Review	Completed	RC1409-000
Temperature Management in Patients Post-Cardiac Arrest	Temperature Management in Patients Post-Cardiac Arrest	Feb 16, 2022	Rapid Review	Completed	RC1407-000
Antibiotic Solutions for Surgical Irrigation	Antibiotic Solutions for Surgical Irrigation	Feb 7, 2022	Rapid Review		RC1408-000
Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19	Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19	Jan 28, 2022	Technology Review	Completed	HD0007-000
Adalimumab for the Treatment of Adults With Non-Infectious Uveitis	Adalimumab for the Treatment of Adults With Non-Infectious Uveitis	Jan 24, 2022	Rapid Review	Completed	RD0063-000
Orthopedic Footwear for People With Lower-Limb Conditions	Orthopedic Footwear for People With Lower-Limb Conditions	Jan 24, 2022	Rapid Review	Completed	RC1406-000
The Small House Model for Long-Term Care	The Small House Model for Long-Term Care In Brief: The Small House Model to Support Older Adults in Long-Term Care	Jan 20, 2022	Environmental Scan	Completed	ES0359-000
Pharmacogenomic Testing in Depression: A 2021 Update	Pharmacogenomic Testing in Depression: A 2021 Update	Jan 18, 2022	Rapid Review	Completed	RC1403-000
Evaluations of Virtual Care	Evaluations of Virtual Care	Jan 12, 2022	Environmental Scan	Complete	ES0358-000
Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma	Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autol…	Jan 10, 2022	Rapid Review	Completed	RC1404-000
Floatation Therapy for Physical Conditions	Floatation Therapy for Physical Conditions	Jan 10, 2022	Rapid Review	Completed	RC1398-000
Clinical Effectiveness of Opioid Substitution Treatment	Clinical Effectiveness of Opioid Substitution Treatment	Jan 10, 2022	Rapid Review	Completed	RC1405-000 - RB1604-000
Remote Monitoring Programs for Cardiac Conditions	OP0549_SummaryTool_considerations_for_the_implementation_of_remote_monitoring_programs_in_canada.pdf OP0549 - Remote Monitoring - Recommendations v7.1-meta.pdf remote_monitoring_for_cardiac_conditions_a_review.pdf OP0549-RM for Cardiac Conditions Final-meta.pdf op0549-rm-for-cardiac-conditions-realist-review-protocol.pdf op0549-remote-monitoring-cardiac-conditions-protocol.pdf realist-review-explainer-e.pdf	Jan 10, 2022	Optimal Use	Completed	OP0549-000
Cost-Effectiveness and Guidelines for Opioid Substitution Treatment	Cost-Effectiveness and Guidelines for Opioid Substitution Treatment	Jan 4, 2022	Rapid Review	Completed	RC1401-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 301 - 325 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Gabapentin for Seizures		Gabapentin for Seizures	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1557-000
Early Biologic Treatment for Inflammatory Bowel Disease		Early Biologic Treatment for Inflammatory Bowel Disease	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1552-000
The Utilization of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 22, 2024	Health Technology Review	Technology Review	Active	HC0094-000
Airway Management in Out-of-Hospital Emergencies		Airway Management in Out-of-Hospital Emergencies	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1555-000
CRISPR Technologies for In Vivo and Ex Vivo Gene Editing	Our Horizon Scan provides an overview of CRISPR technologies and their current and potential roles in health care.	Final Report	Oct 21, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH00127-000 - HC0092-000
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis		BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1549-000
datopotamab deruxtecan			Oct 18, 2024	Reimbursement Review		Cancelled	PC0384-000
Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis			Oct 16, 2024	Health Technology Review	Technology Review	In Progress	HC0093-000
bimekizumab		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0809-000
leniolisib			Oct 10, 2024	Reimbursement Review		Suspended	SR0792-000
metreleptin		Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0784-000
The Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 10, 2024	Health Technology Review	Observational Study	Active	OS0011-000
Prostate Cancer		Final Report	Oct 9, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0050-000
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer		Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer	Oct 4, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1550-000
insulin icodec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 3, 2024	Reimbursement Review		Complete	SR0790-000
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant		Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant	Oct 2, 2024	Health Technology Review	Rapid Review	Completed	RC1553-000
etranacogene dezaparvovec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Sep 26, 2024	Reimbursement Review		Complete	SG0805-000
nivolumab		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Sep 26, 2024	Reimbursement Review		Complete	PC0339-000
Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years		Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18…	Sep 26, 2024	Health Technology Review	Technology Review	Completed	HE0054-000
Pharmaceutical Reviews Update — Issue 51			Sep 26, 2024	Reimbursement Review	Pharmaceutical Review Update
avatrombopag		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Sep 25, 2024	Reimbursement Review		Complete	SR0721-000
Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries		Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries	Sep 25, 2024	Health Technology Review	Rapid Review	Completed	RC1547-000
maralixibat		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Sep 20, 2024	Reimbursement Review		Complete	SR0780-000
Continuously Diffused Therapy for Wound Healing	To inform decisions about continuously diffused oxygen (CDO) therapy for wound healing, we identified and summarized literature comparing the clinical effectiveness and cost-effectiveness of CDO therapy versus conventional wound care.	Continuously Diffused Therapy for Wound Healing	Sep 20, 2024	Health Technology Review	Rapid Review	Completed	RC1548-000
bimekizumab		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Sep 19, 2024	Reimbursement Review		Complete	SR0803-000